Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.68 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.68 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12621027 | 1.00 | POLB (0.87) | POLBLMNAHPGDALDH1A1DUSP3 | |
| Hydrochloric Acid SCHEMBL27606633 | 0.98 | POLB (0.84) | POLBLMNAHPGDALDH1A1DUSP3 | |
| SCHEMBL17465272 | 0.93 | POLB (1.00) | POLBLMNAHPGDALDH1A1DUSP3 | |
| SCHEMBL10724841 | 0.90 | POLB (0.81) | POLBLMNAHPGDALDH1A1ALOX15 | |
| SCHEMBL2726277 | 0.88 | EPHX2 (0.75) | POLBLMNAHPGDALDH1A1DUSP3 | |
| SCHEMBL2646094 | 0.85 | HPGD (0.70) | POLBLMNAHPGDALDH1A1KMT2A | |
| SCHEMBL20449050 | 0.85 | POLB (0.86) | POLBLMNAHPGDALOX15KMT2A | |
| SCHEMBL2378399 | 0.84 | HPGD (0.73) | POLBLMNAHPGDALDH1A1DUSP3 | |
| SCHEMBL14980308 | 0.83 | POLB (0.72) | POLBLMNAHPGDALOX15KMT2A | |
| SCHEMBL82433 | 0.83 | ALDH1A1 (0.72) | POLBLMNAHPGDALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| CN-115003671-B | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-115003671-A | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022146201-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-07-07 | — | — | WO | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| EP-3786156-A1 | 10H-PHENOTHIAZINE FERROPTOSIS INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Chengdu Henghao Investment Co. Limited (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | POLB 1133/4885LMNA 4816/4885HPGD 2638/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | POLB 4627/4885LMNA 3766/4885HPGD 3691/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | POLB 958/4885LMNA 1745/4885HPGD 534/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | POLB 2675/4885LMNA 114/4885HPGD 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.